Title

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication
Analgesic Efficacy of Transversus Abdominis Plane Block Versus Local Injection in Postoperative Pain Management Following Minimally Invasive Gynecological Surgery
  • Phase

    N/A
  • Study Type

    Interventional
  • Study Participants

    220
The purpose of this study is to determine if there is a better method of administering pain medication prior to minimally invasive gynecological surgery so that postoperative pain and/or narcotic usage may be minimized. Currently, no standard of care exists regarding the use of local pain medications in minimally invasive gynecological surgery and practices vary widely among physicians, even within the same institution.

The two methods of preemptive pain medication that this study will be looking at is the transversus abdominis plane (TAP) block and the local injection of pain medication at the areas of the skin incisions. TAP block is a procedure performed by a specially trained pain management anesthesiologist in which there is an injection of a local pain medication into the abdominal wall, specifically in a space where the nerves that are responsible for postoperative pain reside. This procedure blocks the ability of the nerves to sense pain and has been found to be successful in decreasing postoperative pain in a number of procedures. The local injection of pain medications at the incision sites has also been found to be beneficial in decreasing postoperative pain. However, it is not known whether one method is superior to the other in decreasing postoperative pain or if the combination of both is best.

Patients that chose to participate are randomly (by chance) assigned to one of three groups: 1) TAP block with pain medication and local injection of normal saline (water) at the incision sites 2) TAP block with normal saline and local injection of pain medication at the incision sites or 3) TAP block with pain medication and local injection of pain medication at the port sites. These procedures are performed while the patient is asleep. Patients will be asked to record their level of pain on a standardized pain scale at one hour, six hours, and twenty-four hours after the surgery. All patients are provided with standard postoperative pain medications as needed.

The hypothesis is that patients receiving both TAP block and local injection of pain medication at the port sites will have less pain postoperatively and require a smaller amount of narcotics than those that receive either the TAP block or local injection of pain medication alone.
This is a prospective, single center, double-blinded, multi-arm parallel group study conducted at a university affiliated medical center. Study approval was obtained from the Saint Barnabas Medical Center institutional review board, and written informed consent was obtained from all study participants.

Patients were randomly assigned to one of three parallel groups in a 1:1:1 ratio, to receive either: treatment transversus abdominis plane (TAP) block and placebo local injection, placebo TAP block and treatment local injection, or treatment TAP block and treatment local injection. This study took place at Saint Barnabas Medical Center in Livingston, New Jersey from May 2011 to October 2013. Patients were recruited from the offices of ten different gynecological surgeons in private practice. Two of the surgeons were gynecological oncologists, and the remainder were general obstetricians/gynecologists that perform minimally invasive gynecological surgery. The TAP blocks were administered by one of four anesthesiologists.

Patients were consented and enrolled in the study by blinded obstetrical and gynecological residents while the patients were in the preoperative area. Each patient was given a standardized informed consent packet detailing the study. Once a patient gave informed consent and was enrolled in the study, independent pharmacists were notified of their enrollment. The pharmacists then assigned participants to one of three possible interventions based on a computer-generated randomization list that was created by the principal investigator prior to commencement of patient enrollment. The pharmacist assigned patients into their appropriate intervention based upon what number participant the patient was in the study. The pharmacist then dispensed the study medications into identical 30 mL syringes labeled study drug and placed them in brown paper bags. The study medication to be administered via TAP block was placed in two 30 mL syringes and placed in a brown paper bag. The study medication to be used for local injection was placed in a single 30 mL syringe and placed in a separate brown paper bag. These bags were then brought to the operating room where they were to be administered. The bag containing the two syringes was given to the anesthesiologists performing the TAP block and the bag with the single syringe was handed to the scrub tech that then later distributed it to the surgeons. The patients, all healthcare providers, and data collectors were blinded as to group allocation. Additionally, both ropivacaine and normal saline are clear and indistinguishable from one another.

The interventions were administered in the operating room once the patients had been placed under general anesthesia, prior to skin incisions. The TAP blocks were administered under ultrasound guidance.

Patients were then prepped and draped for surgery. Prior to proceeding to skin incisions the surgeons administered 2 mL of local injection subcutaneously at the intended port site locations. If additional port sites were deemed necessary during the procedure study drug was administered in a similar fashion prior to those skin incisions being made.

Postoperatively all patients received a standardized analgesia regimen. Specifically, for mild pain, oxycodone/acetaminophen 5/325 mg one tablet orally every four hours; for moderate pain, oxycodone/acetaminophen 5/325 mg two tablets orally every six hours, and for severe pain, hydromorphone 1 mg every 3 hours intravenously.
Study Started
May 31
2011
Primary Completion
Oct 31
2013
Study Completion
Oct 31
2013
Results Posted
Apr 14
2015
Estimate
Last Update
Apr 14
2015
Estimate

Drug ropivacaine

Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.

  • Other names: Naropin

Treatment TAP, placebo local injection Active Comparator

Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.

Placebo TAP, treatment local injection Active Comparator

Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.

Treatment TAP, treatment local injection Active Comparator

Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.

Criteria

Inclusion Criteria:

Female
Undergoing gynecological robotic and/or laparoscopic surgery
Overnight hospitalization expected

Exclusion Criteria:

Fibromyalgia
Chronic pelvic pain
Relevant drug allergy
Conversion to laparotomy
Pregnant

Summary

Treatment TAP, Placebo Local Injection

Placebo TAP, Treatment Local Injection

Treatment TAP, Treatment Local Injection

All Events

Event Type Organ System Event Term

Postoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively

A Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Treatment TAP, Placebo Local Injection

4.04
units on a scale (Mean)
Standard Deviation: 2.9

Placebo TAP, Treatment Local Injection

5.09
units on a scale (Mean)
Standard Deviation: 2.46

Treatment TAP, Treatment Local Injection

4.4
units on a scale (Mean)
Standard Deviation: 2.53

Postoperative Pain on a Visual Analogue Pain Scale at Six Hours Postoperatively

A Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Treatment TAP, Placebo Local Injection

3.53
units on a scale (Mean)
Standard Deviation: 2.62

Placebo TAP, Treatment Local Injection

3.5
units on a scale (Mean)
Standard Deviation: 1.93

Treatment TAP, Treatment Local Injection

3.33
units on a scale (Mean)
Standard Deviation: 2.53

Postoperative Pain on a Visual Analogue Pain Scale at Twenty-four Hours Postoperatively

A Visual Analogue Scale was used. The scale range was 0 to 10 in increments of one. 0 was no pain and 10 was worst pain possible.

Treatment TAP, Placebo Local Injection

3.36
units on a scale (Mean)
Standard Deviation: 2.15

Placebo TAP, Treatment Local Injection

3.56
units on a scale (Mean)
Standard Deviation: 2.13

Treatment TAP, Treatment Local Injection

3.51
units on a scale (Mean)
Standard Deviation: 2.59

Time Until First Request for Pain Medication

Treatment TAP, Placebo Local Injection

46.0
minutes (Median)
Inter-Quartile Range: 18.0 to 104.0

Placebo TAP, Treatment Local Injection

31.0
minutes (Median)
Inter-Quartile Range: 20.0 to 56.0

Treatment TAP, Treatment Local Injection

28.0
minutes (Median)
Inter-Quartile Range: 13.0 to 78.0

Total Narcotic Usage in Morphine Equivalents

Treatment TAP, Placebo Local Injection

20.09
mg (Mean)
Standard Deviation: 11.6

Placebo TAP, Treatment Local Injection

23.14
mg (Mean)
Standard Deviation: 12.3

Treatment TAP, Treatment Local Injection

20.68
mg (Mean)
Standard Deviation: 12.8

Total

183
Participants

Age, Continuous

54.0
years (Mean)
Standard Deviation: 10.7

BMI (m/kg2)

30.8
kg/m^2 (Mean)
Standard Deviation: 7.3

Height (inches)

64.3
inches (Mean)
Standard Deviation: 2.5

Weight (kg)

82.0
kg (Mean)
Standard Deviation: 19.6

Region of Enrollment

Sex: Female, Male

Overall Study

Treatment TAP, Placebo Local Injection

Placebo TAP, Treatment Local Injection

Treatment TAP, Treatment Local Injection